Ordering of the N-terminus of human MDM2 by small molecule inhibitors.
暂无分享,去创建一个
L. Poppe | J. B. Jordan | P. Schnier | Xin Huang | P. Yakowec | A. Long | Jeffrey C. Lewis | Evelyn Yang | Y. Rew | K. Michelsen | Jing Zhou | Klaus Michelsen | J. Lewis
[1] L. Kay,et al. A Gradient-Enhanced HCCH-TOCSY Experiment for Recording Side-Chain 1H and 13C Correlations in H2O Samples of Proteins , 1993 .
[2] Ad Bax,et al. Methodological advances in protein NMR , 1993 .
[3] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[4] V. Hu. The Cell Cycle , 1994, GWUMC Department of Biochemistry Annual Spring Symposia.
[5] M. Doyle,et al. Tight binding affinities determined from thermodynamic linkage to protons by titration calorimetry. , 1995, Methods in enzymology.
[6] S. Grzesiek,et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.
[7] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[8] J. Thornton,et al. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.
[9] A. Jochemsen,et al. MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.
[10] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[11] K. Wüthrich,et al. Torsion angle dynamics for NMR structure calculation with the new program DYANA. , 1997, Journal of molecular biology.
[12] S F Howard,et al. Molecular characterization of the hdm2-p53 interaction. , 1997, Journal of molecular biology.
[13] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[14] J H Lakey,et al. Heat does not come in different colours: entropy-enthalpy compensation, free energy windows, quantum confinement, pressure perturbation calorimetry, solvation and the multiple causes of heat capacity effects in biomolecular interactions. , 2001, Biophysical chemistry.
[15] Robert N. Goldberg,et al. Thermodynamic Quantities for the Ionization Reactions of Buffers , 2002 .
[16] M. McCoy,et al. Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] L. Vassilev,et al. Targeting the p53–MDM2 interaction to treat cancer , 2004, British Journal of Cancer.
[18] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[19] J. Deschamps,et al. Structure-based design of potent non-peptide MDM2 inhibitors. , 2005, Journal of the American Chemical Society.
[20] Maxwell D Cummings,et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.
[21] A. Hamilton,et al. Strategies for targeting protein-protein interactions with synthetic agents. , 2005, Angewandte Chemie.
[22] Paul N Barlow,et al. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. , 2005, Journal of molecular biology.
[23] Su Qiu,et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.
[24] T. Holak,et al. Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.
[25] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[26] Dajun Yang,et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.
[27] Rafael Brüschweiler,et al. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. , 2008, Journal of the American Chemical Society.
[28] Xin Huang,et al. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.
[29] Ernst Schönbrunn,et al. Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX* , 2009, The Journal of Biological Chemistry.
[30] Chandra S Verma,et al. Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies , 2010, Cell cycle.
[31] Matteo Magnani,et al. Molecular Interaction Fields and 3D-QSAR Studies of p53-MDM2 Inhibitors Suggest Additional Features of Ligand-Target Interaction , 2010, J. Chem. Inf. Model..
[32] C. Prives,et al. The C-terminus of p53 binds the N-terminal domain of MDM2 , 2010, Nature Structural &Molecular Biology.
[33] Wei Wang,et al. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery , 2010, Cell cycle.
[34] Gareth Davies,et al. MDM4 binds ligands via a mechanism in which disordered regions become structured , 2010, FEBS letters.
[35] S. Chi,et al. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins. , 2011, Journal of the American Chemical Society.
[36] Alexander Dömling,et al. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. , 2011, Angewandte Chemie.
[37] Weirong Yuan,et al. Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined. , 2012, Journal of the American Chemical Society.
[38] Y. Muto,et al. Structural insights into the dual-targeting mechanism of Nutlin-3. , 2012, Biochemical and biophysical research communications.
[39] J. Canon,et al. Structure-based design of novel inhibitors of the MDM2-p53 interaction. , 2012, Journal of medicinal chemistry.